Ability Biotherapeutics, a biotechnology company developing logic-gated antibody therapies for cancer and autoimmune diseases, announced the appointment of Angèle Maki, PhD, as Chief Business Officer. Giles Day, CEO and Co-Founder of Ability, said the company is thrilled to have Maki join the leadership team, noting her extensive experience in deal-making, licensing, and strategic partnerships will be a significant asset as Ability advances its programs.
Health Technology Insights: Laigo Bio Secures €11.5Million Seed to Advance Suretac Therapies
Dr. Maki brings more than twenty years of experience in the biopharmaceutical industry, including senior roles in business development, licensing, and corporate venture at both emerging biotech companies and global pharmaceutical firms. Her career includes positions at Medarex, now part of Bristol Myers Squibb, Genentech, Merck & Co., Eli Lilly, and Callio Therapeutics.
In her new role, Dr. Maki will lead Ability’s business development efforts, focusing on global partnerships and investor relations to support the company’s growth. These initiatives aim to advance Ability’s autoimmune and oncology programs developed through the AbiLeap platform toward clinical trials while exploring opportunities to create new, highly specific logic-gated antibody therapies across multiple indications.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 4 December 2025
Day emphasized that Dr. Maki’s decision to join the executive team after serving on Ability’s board reflects her confidence in the company’s vision and momentum. He noted that her extensive biotech and pharmaceutical experience, combined with a strong global network, will be invaluable as the company builds strategic collaborations.
Dr. Maki said she is excited to join Ability Biotherapeutics at this pivotal stage. She highlighted the company’s unique approach to antibody therapies using logic-gated design supported by generative AI and one of the largest human antibody databases as a major driver for innovation. She looks forward to contributing to the company’s progress toward first-in-human studies and making a meaningful difference for patients.
Ability Biotherapeutics continues to expand its pipeline of logic-gated antibody therapeutics through the AbiLeap platform and is actively seeking partnerships and collaborations with biotech and pharmaceutical companies. Dr. Maki and other members of the leadership team will attend the J.P. Morgan Healthcare Conference in January 2026 to engage in discussions on strategic partnerships and investment opportunities.
Health Technology Insights: Natera Acquires Foresight Diagnostics
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
